A 2nd case series on IL-6 inhibition in COVID-ARDS.

- n=21
- no control group
- ~1/3 got better
- ~1/3 got worse
- ~1/3 was the same (still in ARDS)
- CRP improved (read: they got the drug)

Can& #39;t make any better clinical decisions based on this.

@EBRheum @isa75012 @PatelAarat @alhkim @LCalabreseDO

Here is the link: https://www.medrxiv.org/content/10.1101/2020.04.01.20048561v1">https://www.medrxiv.org/content/1...